ABSTRACT
Background Prior observation has shown differences in COVID-19 hospitalization rates between SARS-CoV-2 variants, but limited information describes differences in hospitalization outcomes.
Methods Patients admitted to 5 hospitals with COVID-19 were included if they had hypoxia, tachypnea, tachycardia, or fever, and data to describe SARS-CoV-2 variant, either from whole genome sequencing, or inference when local surveillance showed ≥95% dominance of a single variant. The average effect of SARS-CoV-2 variant on 14-day risk of severe disease, defined by need for advanced respiratory support, or death was evaluated using models weighted on propensity scores derived from baseline clinical features.
Results Severe disease or death within 14 days occurred for 950 of 3,365 (28%) unvaccinated patients and 178 of 808 (22%) patients with history of vaccination or prior COVID-19. Among unvaccinated patients, the relative risk of 14-day severe disease or death for Delta variant compared to ancestral lineages was 1.34 (95% confidence interval [CI] 1.13-1.55). Compared to Delta variant, this risk for Omicron patients was 0.78 (95% CI 0.62-0.97) and compared to ancestral lineages was 1.04 (95% CI 0.84-1.24). Among Omicron and Delta infections, patients with history of vaccination or prior COVID-19 had one-half the 14-day risk of severe disease or death (adjusted hazard ratio 0.46, IQR 0.34-0.62) but no significant outcome difference between Delta and Omicron infections.
Conclusions Although the risk of severe disease or death for unvaccinated patients with Omicron was lower than Delta, it was similar to ancestral lineages. Severe outcomes were less common in vaccinated patients, but there was no difference between Delta and Omicron infections.
Competing Interest Statement
The Maryland Department of Health collaborates for research with BioRad, Hologic, and DiaSorin. JB has equity/entitlement to future royalties in miDiagnostics. BG is a member of the FDA Pulmonary-Asthma Drug Advisory Committee and has received consulting fees from Janssen Research and Development, LLC, Gilead Sciences, Inc, and Atea Pharmaceuticals, Inc
Funding Statement
Support was provided by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) to the Johns Hopkins Center of Excellence in Influenza Research and Surveillance (HHSN272201400007C), NIH RADx-UP initiative (R01DA045556-04S1) and with the National Institute on Drug Abuse to the HIV Prevention Trials Network Laboratory Center (UM1AI068613), National Heart, Lung, and Blood Institute, NIH and National Institute of Biomedical Imaging and Bioengineering, NIH to the NIH RADx-Tech program (3U54HL143541-02S2 and U54EB007958-12S1), Centers for Disease Control and Prevention (contract 75D30121C11061), Maryland Department of Health, the Johns Hopkins University President's Fund Research Response, the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, John Hopkins inHealth, and the Johns Hopkins Precision Medicine Initiative. The contents are solely the responsibility of the authors and do not necessarily represent the official view of the sponsors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research was conducted under Johns Hopkins institutional review board protocol IRB00300364 with a waiver of consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
SARS-CoV-2 genomes were uploaded to Global Initiative on Sharing All Influenza Data (GISAID).